Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial

Priyadarshani Galappatthy, Yasindu C Waniganayake, Mohomad I M Sabeer, Thusitha J Wijethunga, Gamini K S Galappatthy, Ruvan Ai Ekanayaka, Priyadarshani Galappatthy, Yasindu C Waniganayake, Mohomad I M Sabeer, Thusitha J Wijethunga, Gamini K S Galappatthy, Ruvan Ai Ekanayaka

Abstract

Background: Leg edema is a common adverse effect of dihydropyridine Calcium Channel Blockers (CCB) that may need dose reduction or drug withdrawal, adversely affecting the antihypertensive efficacy. Leg edema is reported to occur less often with (S)-amlodipine compared to conventional racemic amlodipine. We aimed to find the incidence of leg edema as a primary outcome and antihypertensive efficacy with (S)-amlodipine compared to conventional amlodipine.

Methods: This prospective, double-blind, controlled clinical trial randomized 172 hypertensive patients, not controlled on beta-blockers (BB) and angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), to either conventional amlodipine (5-10 mg; n = 86) or (S)-amlodipine (2.5-5 mg; n = 86), while continuing their previous anti-hypertensive medications. Sample was sufficient to find a difference in edema between the interventions with 80 % power at 5 % significance level. Intension to treat analysis (ITT) for safety data and per protocol analysis for efficacy data was performed. Fischer's exact test was applied to observe difference between responder rates and proportions of subjects having peripheral edema in the two groups. Pitting edema test scores were compared using Mann-Whitney test.

Results: Altogether 146 patients (amlodipine, n = 76 and (S)-amlodipine, n = 70) completed 120 days treatment. Demographic variables and treatment adherence were comparable in the two groups. Incidence of new edema after randomization was 31.40 % in test group and 46.51 % in control group [p = 0.03; absolute risk reduction (ARR) = 15.1 %; Number Needed to Treat (NNT) = 7, ITT analysis]. Pitting edema score and patient rated edema score increased significantly in the control compared to test group (p = 0.038 and 0.036 respectively) after treatment period. Edema scores increased significantly in the control group from baseline (p < 0.0001). Responders in blood pressure were 98.57 % in test and 98.68 % in control group. Most common adverse events (AE) were pitting edema and increased urinary frequency. Incidence of all AEs other than edema was similar in both groups. Two serious AEs occurred unrelated to therapy. Biochemical and ECG parameters in the two groups were comparable.

Conclusions: In hypertensive patients not controlled on prior BB and ACEI/ARB therapy, addition of (S)-amlodipine besylate at half the dose of conventional amlodipine provides better tolerability with reduced incidence of peripheral edema, and equal antihypertensive efficacy compared to amlodipine given at usual doses.

Trial registration: Sri Lanka Clinical Trials registry: www.slctr.lk, SLCTR/2013/006.

Keywords: (S)-Amlodipine; Calcium channel blocker; Conventional racemic amlodipine; Hypertension; Leg edema; Randomized controlled clinical trial.

Figures

Fig. 1
Fig. 1
Consort diagram showing the flow of participants

References

    1. Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich) 2006;8(1):53–56. doi: 10.1111/j.1524-6175.2005.04140.x.
    1. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32–39. doi: 10.1161/HYPERTENSIONAHA.109.131300.
    1. Chrysant SG, Lee J, Melino M, Karki S, Heyrman R. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010;24(11):730–738. doi: 10.1038/jhh.2010.5.
    1. Hong B-K, Park CG, Kim KS, Yoon MH, Yoon HJ, Yoon JH, et al. Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan. Am J Cardiovasc Drugs. 2012;12(3):189–195. doi: 10.2165/11597410-000000000-00000.
    1. Sica DA. Calcium channel blocker-related periperal edema: can it be resolved? J Clin Hypertens (Greenwich) 2003;5(4):291–294. doi: 10.1111/j.1524-6175.2003.02402.x.
    1. Messerli F. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens. 2001;14(9):978–979. doi: 10.1016/S0895-7061(01)02178-1.
    1. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124(2):128–135. doi: 10.1016/j.amjmed.2010.08.007.
    1. Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate-a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270–1280. doi: 10.1097/HJH.0b013e3283472643.
    1. Pedrinelli R, Dell’Omo G, Nuti M, Menegato A, Balbarini A, Mariani M. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens. 2003;21(10):1969–1973. doi: 10.1097/00004872-200310000-00026.
    1. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol. 1997;79(4):431–435. doi: 10.1016/S0002-9149(96)00781-3.
    1. Pepine CJ, Cooper-DeHoff RM, Weiss RJ, Koren M, Bittar N, Thadani U, et al. Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. Am J Cardiol. 2003;91(3):274–279. doi: 10.1016/S0002-9149(02)03154-5.
    1. Messerli F. Vasodilatory edema: synergistic effect of high-dose calcium antagonist/ace inhibitor combination therapy. Am J Hypertens. 1999;12(4):121. doi: 10.1016/S0895-7061(99)80424-5.
    1. De la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens. 2009;23(8):503–511. doi: 10.1038/jhh.2008.157.
    1. Chrysant SG. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens (Greenwich) 2008;10(9):716–722. doi: 10.1111/j.1751-7176.2008.00006.x.
    1. Wang R-X, Jiang W-P, Li X-R, Lai L-H. Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008;63(6):470–474.
    1. Gharpure MM, BhaWal BM, Ranade PV, Deshmukh RD, Mehta SR. Inventors; Emcure Pharmaceuticals Limited, Assignee. US patent 8,445,688 B2. 2013.
    1. Liu F, Qiu M, Zhai S-D. Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension:a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2010;71(1):1–29. doi: 10.1016/j.curtheres.2010.02.005.
    1. Kim SA, Park S, Chung N, Lim DS, Yang JY, Oh BH, et al. Efficacy and safety profiles of a new S (−)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial. Clin Ther. 2008;30(5):845–857. doi: 10.1016/j.clinthera.2008.05.013.
    1. Pathak L, Hiremath, Kerkar PG, Manade VG. Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial. J Assoc Physicians India. 2004;52:197–202.
    1. Mehta A. S amlodpine besylate, a chirally pure calcium channel blocker, for treatment of essential hypertension and angina. J Therapeutic Advances. 2011;3:2–13.
    1. Anonymous Safety and efficacy of S-amlodipine-SESA study. JAMA. 2003;2(8):81–5.
    1. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328(7440):634–640. doi: 10.1136/bmj.328.7440.634.
    1. Brodovicz KG, McNaughton K, Uemura N, Meininger G, Girman CJ, Yale SH. Reliability and feasibility of methods to quantitatively assess peripheral edema. Clin Med Res. 2009;7(1–2):21–31. doi: 10.3121/cmr.2009.819.
    1. Malacco E, Varì N, Capuano V, Spagnuolo V, Borgnino C, Palatini P. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther. 2003;25(11):2765–2780. doi: 10.1016/S0149-2918(03)80332-6.
    1. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002;4(6):479–482. doi: 10.1007/s11886-002-0110-9.
    1. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 2003;5(5):330–335. doi: 10.1111/j.1524-6175.2003.02216.x.
    1. Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991;84(6):341–344.
    1. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563–580. doi: 10.1016/j.clinthera.2007.03.018.
    1. Fogari R, Zoppi A, Derosa G, Mugellini A, Lazzari P, Rinaldi A, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21(3):220–224.
    1. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031. doi: 10.1016/S0140-6736(04)16451-9.
    1. Anderson RB, Hollenberg NK, Williams GH. Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Arch Intern Med. 1999;159(7):693–700. doi: 10.1001/archinte.159.7.693.
    1. Fogari R, Malamani G, Zoppi A, Mugellini A, Rinaldi A, Fogari E, Perrone T. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. Clin Ther. 2007;29(3):413–418. doi: 10.1016/S0149-2918(07)80079-8.
    1. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. J Hum Hypertens. 1999;13(7):477–483. doi: 10.1038/sj.jhh.1000855.
    1. Roberto JS F, Suely G, Mari M, Wille O, behalf of the valsartan/HCTZ combination therapy in Brazil study group Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild to moderate hypertensive Brazilian population. Blood Press. 2003;12:41–47. doi: 10.1080/080380203100022399.
    1. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32(20):2499–2506. doi: 10.1093/eurheartj/ehr177.
    1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2014;311(5):507–520. doi: 10.1001/jama.2013.284427.
    1. Gradman AH. Rationale for Triple-Combination Therapy for Management of High Blood Pressure. J Clin Hypertens. 2010;12(11):869–878. doi: 10.1111/j.1751-7176.2010.00360.x.
    1. Oh G-C, Lee H-Y, Kang H-J, Zo J-H, Choi D-J, Oh B-H. Quantification of pedal edema during treatment with S (−)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical. Clin Ther. 2012;34(9):1940–1947. doi: 10.1016/j.clinthera.2012.08.003.
    1. Damasceno A, Santos A, Pestana M, Serrão P, Caupers P, Soares-da-Silva P, Polónia J. Acute hypotensive, natriuretic, and hormonal effects of nifedipine in salt-sensitive and salt-resistant black normotensive and hypertensive subjects. J Cardiovasc Pharmacol. 1999;34(3):346–353. doi: 10.1097/00005344-199909000-00005.
    1. Esin RA, Essien OE, Andy J. Amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res. 1994;55(9):1112–1116. doi: 10.1016/S0011-393X(05)80282-6.
    1. Menard J, Bellet M. Calcium antagonists-ACE inhibitors combination therapy: objectives and methodology of clinical development. J Cardiovasc Pharmacol. 1993;21(Suppl 2):S49–S54. doi: 10.1097/00005344-199321002-00009.
    1. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62(3):443–462. doi: 10.2165/00003495-200262030-00003.
    1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25(6):1105–1187. doi: 10.1097/HJH.0b013e3281fc975a.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner